Description
Human Menopausal Gonadotropin (HMG) is a purified glycoprotein hormone preparation containing both follicle-stimulating hormone (FSH) and luteinizing hormone (LH) activity in approximately 1:1 ratio, derived from pooled postmenopausal urinary sources through established purification processes. HMG represents one of the earliest characterized gonadotropin preparations in the academic and clinical research literature spanning multiple decades. The FSH and LH glycoproteins in HMG are both α/β heterodimeric proteins — sharing the common α-subunit of the glycoprotein hormone family (also shared with HCG and TSH) while carrying unique β-subunits that confer specific receptor binding to the FSH receptor (FSHR) and LH/choriogonadotropin receptor (LHCGR) respectively. This 75 IU lyophilized presentation is offered for laboratory research applications investigating comparative gonadotropin receptor pharmacology, dual FSH/LH receptor activation research, glycoprotein hormone chemistry, and comparative pharmacology across the broader glycoprotein hormone family. HMG has been extensively characterized in academic research literature for FSHR and LHCGR receptor binding, cAMP/PKA signaling cascade activation, and downstream steroidogenic and folliculogenic pathway research in cell research models. The compound is supplied here strictly for laboratory research applications and remains a research-use-only compound in this presentation.
Benefits (Research Focus)
• Dual FSHR / LHCGR receptor pharmacology — studied for combined FSH receptor and LH/choriogonadotropin receptor binding activity in the same preparation
• Comparative gonadotropin research — investigated as a research reference alongside purified recombinant FSH, LH, and HCG preparations for comparative pharmacology
• Glycoprotein hormone chemistry research — explored as a mixed FSH/LH glycoprotein preparation for comparative α/β heterodimeric protein research
• cAMP / PKA signaling research — examined for Gs-coupled cAMP signaling cascade activation across both FSHR and LHCGR receptor pathways
• Urinary-derived glycoprotein research — researched as one of the historical urinary-derived glycoprotein hormone preparations in academic and clinical research literature
What Researchers Look At
• Comparative FSHR versus LHCGR receptor binding affinity and downstream cAMP signaling activation
• Verified FSH IU and LH IU potency ratios and comparative research versus recombinant FSH and LH preparations
• Glycosylation pattern characterization and comparative research versus recombinant glycoprotein hormone preparations
• α-subunit and β-subunit interaction chemistry across the mixed FSH/LH preparation
• Comparative pharmacology versus HCG (shared α-subunit, related glycoprotein hormone family)
Quick Specs
• Form: Lyophilized white powder
• Net Content: 75 IU per vial (approximately equal FSH and LH activity)
• Quantity: 1 vial
• Appearance: White to off-white lyophilizate
• Reconstitution: Bacteriostatic or sterile water (added by the end researcher)
• Purity: ≥99% (per COA)
• Identity: Verified by potency assay (FSH IU + LH IU per COA)
• Storage: Protect from light
Identity Basics
• Compound: Human Menopausal Gonadotropin (HMG)
• Synonyms: Menotropin; hMG; menopausal gonadotropin; mixed urinary gonadotropin; FSH/LH glycoprotein preparation
• Class: Mixed glycoprotein hormone preparation containing both FSH and LH activity; α/β heterodimeric proteins; FSHR + LHCGR receptor agonist research compound
• Composition: Follicle Stimulating Hormone (FSH, ~35,500 Da glycosylated heterodimer) + Luteinizing Hormone (LH, ~29,600 Da glycosylated heterodimer) in approximately 1:1 ratio by IU activity
• Source: Purified from pooled postmenopausal human urinary source through established purification processes
• Approximate Molecular Weight: Combined mixed preparation containing two glycoprotein hormones of different molecular weights (FSH ~35,500 Da; LH ~29,600 Da)
• CAS: 61489-71-2 (menotropin / HMG)
⚠️ Disclaimer
- This product is intended for laboratory research use only.
- Not for human or veterinary use.
- Not approved for diagnostic, therapeutic, or medical applications in this presentation.
- Gonadotropin preparations require precise dosing, laboratory monitoring, and medical supervision for any clinical application — this preparation is not supplied or intended for such use.
- Handle using appropriate laboratory safety procedures and personal protective equipment.
COA Verification Notice: Even if the vial label or product image states a certain concentration, always go by the COA for the true verified value. We reference the COA to determine the verified FSH IU and LH IU potency and purity of each batch, regardless of what the label or product image indicates. For HMG specifically, we prioritize verified dual-potency testing (FSH IU + LH IU separately) as underdosing and misrepresented FSH/LH ratios are documented industry-wide concerns for grey-market urinary-derived glycoprotein material.
Third-Party Testing
• [COA links for the HMG 75 IU batch to be added once analytical testing is complete — including verified FSH IU and LH IU dual-potency assay]
